TRVI Trevi Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TRVI

Price (delayed)

$14.46

Market cap

$2.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.34

Enterprise value

$2.01B

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 73
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 9

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF ...

Highlights
The equity has surged by 87% since the previous quarter and by 62% year-on-year
Trevi Therapeutics's quick ratio has surged by 65% YoY and by 51% QoQ
The EPS has increased by 19% YoY but it has decreased by 6% QoQ
Trevi Therapeutics's net income has decreased by 12% from the previous quarter and by 8% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.trevitherapeutics.com
Peers: ACAD AMRN AXSM AGEN

Key stats

What are the main financial stats of TRVI

TRVI stock price

How has the Trevi Therapeutics stock price performed over time
Intraday
-5.12%
1 week
-3.66%
1 month
-19.49%
1 year
72.55%
YTD
15.5%
QTD
-22.47%

Financial performance

How have Trevi Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.56M
Net income
-$51.11M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 16% YoY and by 13% from the previous quarter
Trevi Therapeutics's net income has decreased by 12% from the previous quarter and by 8% YoY

Price vs fundamentals

How does TRVI's price correlate with its fundamentals

Growth

What is Trevi Therapeutics's growth rate over time

Valuation

What is Trevi Therapeutics stock price valuation
P/E
N/A
P/B
6.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 19% YoY but it has decreased by 6% QoQ
The equity has surged by 87% since the previous quarter and by 62% year-on-year
The P/B is 82% above the 5-year quarterly average of 3.7 but 15% below the last 4 quarters average of 7.9

Efficiency

How efficient is Trevi Therapeutics business performance
Trevi Therapeutics's return on invested capital has surged by 58% YoY and by 17% QoQ
Trevi Therapeutics's return on equity has increased by 43% YoY and by 3.7% QoQ
TRVI's ROA is up by 41% YoY and by 3.4% from the previous quarter

Dividends

What is TRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRVI.

Financial health

How did Trevi Therapeutics financials performed over time
The total assets has surged by 84% since the previous quarter and by 59% year-on-year
TRVI's current ratio has surged by 66% year-on-year and by 51% since the previous quarter
Trevi Therapeutics's debt is 100% less than its equity
The equity has surged by 87% since the previous quarter and by 62% year-on-year
Trevi Therapeutics's debt has decreased by 32% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.